Jefferies Maintains Buy on Spyre Therapeutics, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Positive 78.8%

Neg 0% Neu 0% Pos 78.8%

Jefferies analyst Akash Tewari maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $47 to $85.